Pirche

PUBLISHED BY

Francesca Raineri, Lukas Frischknecht, Jakob Nilsson, Fabian Rössler, Claudia Cavelti-Weder, Seraina von Moos, Thomas Schachtner

PUBLISHED IN

Transplant International

PATIENTS

455

ABSTRACT

HIGHLIGHTS

Patients receiving simultaneous pancreas/kidney transplants (SPKTRs) have a higher risk (11.2% vs. 3.1%) of developing new donor-specific antibodies (dnDSA) within the first year after transplant compared to kidney-only transplant recipients (KTRs), but this difference disappears by 10 years post-transplant.

In SPKTRs, the presence of preformed DSA (pre-existing antibodies) increases the risk of developing dnDSA by almost 3 times (HR 2.872), and each year younger the donor's age increases this risk by 6% (HR 0.943).

A higher number of mismatched epitopes within the HLA-DQ locus, as calculated by the PIRCHE-II algorithm, is a strong predictor of dnDSA development in both SPKTRs and KTRs, independent of other risk factors.

While HLA-DQ mismatches are crucial, the total PIRCHE-II score, which considers all HLA mismatches, was not an independent risk factor for dnDSA development, suggesting that its use in post-transplant risk assessment should be approached with caution.

‍

back to key milestones

2024

Solid Organ Transplant

Assessing the Predictive Power of PIRCHE-II Scores for the Development of De Novo Donor-Specific Antibodies After Simultaneous Pancreas-Kidney Transplantation

PUBLISHED BY

PUBLISHED IN

PATIENTS

ABSTRACT

HIGHLIGHTS

Contact us